Illumina Inc. has recently expanded its oncology menu for NovaSeq X Series customers, delivering their flagship oncology products on their most powerful sequencers to enable comprehensive genomic profiling at greater scale and lower costs. The company began offering the high-throughput version of TruSight Oncology 500 (TSO 500 HT) and the latest version of their distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), in recent months. These assays allow labs to expand oncology testing research of tissue and liquid biopsy samples with new sequencing economics, faster run times, and broader batch sizes on the NovaSeq X Series for the first time.
Everett Cunningham, Illumina’s chief commercial officer, expressed excitement about delivering these flagship oncology assays to customers, now fully tested and supported on the NovaSeq X. He emphasized that empowering labs to scale distributed comprehensive genomic profiling can help advance the use of CGP in clinical oncology research and drive precision oncology forward.
Comprehensive genomic profiling (CGP) evaluates hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample to enable therapy selection research. TSO 500 HT on the NovaSeq X Series offers increased throughput with impactful sequencing economic improvements compared to the NovaSeq 6000 System. Illumina plans to expand TSO 500 HT to the company’s NextSeq 1000 and NextSeq 2000 Systems later this quarter.
TSO 500 ctDNA v2 on the NovaSeq X Series enables a faster, more sensitive, and streamlined liquid biopsy CGP workflow from minimally invasive blood samples for solid tumor therapy selection research, now in a fully supported and verified workflow. Laura Knight from Almac Diagnostic Services praised the availability of Illumina TSO 500 ctDNA v2 on the NovaSeq X Plus platform, highlighting the potential for comprehensive genomic profiling.
The TSO 500 ctDNA v2 assay offers improvements such as transformative sequencing economics, faster sequencing run times, resulting in a three-day total assay turnaround time, and more sustainable logistics with ambient temperature shipping for consumables. This advancement is expected to accelerate oncology research and diagnostic development, contributing to precision medicine.
The TruSight Oncology 500 portfolio is a research-use-only pan-cancer portfolio that allows comprehensive genomic profiling from tissue or liquid biopsies. It identifies known and emerging tumor biomarkers across 523 genes using DNA and RNA from tumor samples to identify key variants critical for cancer development. Additionally, it assesses key genomic signatures like tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD).
Illumina’s focus on innovation has positioned them as a global leader in DNA sequencing and array-based technologies, serving customers in research, clinical, and applied markets. The company’s products are used in various applications in life sciences, oncology, reproductive health, agriculture, and other emerging segments. For more information on Illumina, visit their website and connect with them on various social media platforms.
